Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as the general partner, has made an additional investment in MyOridge Inc. (Head office: Sakyo-ku, Kyoto; Representative Director: Naohiro Makita), a venture company that utilizes the results of research at Kyoto University.

Outline of this investment
MyOridge is a venture company established by Dr. Kazunari Minami (former Assistant Professor at the iCeMS) and others based on research results from the Institute for Integrated Cell-Material Sciences (iCeMS) at Kyoto University. The company aims to contribute to the regenerative medicine industry with its unique iPS cell-derived cardiomyocyte-related technology and other technologies for developing media for regenerative medicine.

The company has been involved in the development and social implementation of infrastructure technologies necessary for cell culture, including the production of iPS cell-derived cardiomyocytes using protein-free culture media, the development of manufacturing processes including collaboration with equipment manufacturers and manufacturers of culture substrates and chemicals, and the development of culture media for cells other than cardiomyocytes using technology cultivated through research into cardiomyocytes. We have been working on the development and social implementation of infrastructural technologies necessary for cell culture.

Kyoto iCAP continues to have high expectations for MyOridge's potential to contribute to the practical application of cellular medicines made from stem cells, especially iPS cells, as a cell engineering company responsible for quality assurance and stable production of cellular medicines, and has concluded an investment agreement jointly with RFI Advisors KK (Representative Director: Hiroaki Sakamoto), a general partner of RFI Advisors, Inc. (Representative Director: Hiroaki Sakamoto), an investment fund whose general partner is RFI Advisors K.K. (Representative Director: Hiroaki Sakamoto), and invested 54 million yen.

Outline of MyOrridge Co.

Establishment	August 2016
Business	Chemically induced stem cell differentiation and manufacturing technology for regenerative cell therapy
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Naohiro Makita